Overview
ASP 8825 - Study in Patients With Painful Diabetic Polyneuropathy
Status:
Terminated
Terminated
Trial end date:
2008-11-01
2008-11-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
To demonstrate the superiority of ASP8825 over placebo and dose response in patients with painful diabetic polyneuropathy.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Astellas Pharma Inc
Criteria
Inclusion Criteria:- Subjects aged 20 - 79 years
- Diabetes mellitus patients with diabetic polyneuropathy who have pain symptom for 26
weeks prior to the study
- Subjects who are compliant with diary completion
Exclusion Criteria:
- Subjects who have pain from other diseases at the evaluating site
- Subjects who have nerve diseases at the evaluating site
- Subjects with foot ulcer or gangrene